PMVP

$0.00

(

+0.00%

)
Quote details

stock

Pmv Pharmaceuticals Inc

NASDAQ | PMVP

1.42

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 17, 2025)

$73.43M

Market Cap

-

P/E Ratio

-1.59

EPS

$1.84

52 Week High

$0.81

52 Week Low

HEALTHCARE

Sector

PMVP Chart

Recent Chart
Price Action

PMVP Technicals

Tags:

PMVP Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue $1.1M
Costof Goods And Services Sold $1.1M
Operating Income -$85M
Selling General And Administrative $27M
Research And Development $59M
Operating Expenses $85M
Investment Income Net -
Net Interest Income $11M
Interest Income $11M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.1M
Income Before Tax -$75M
Income Tax Expense -$16M
Interest And Debt Expense -
Net Income From Continuing Operations -$59M
Comprehensive Income Net Of Tax -
Ebit -$85M
Ebitda -$84M
Net Income -$59M

Revenue & Profitability

Earnings Performance

PMVP Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $191M
Total Current Assets $176M
Cash And Cash Equivalents At Carrying Value $41M
Cash And Short Term Investments $41M
Inventory -
Current Net Receivables -
Total Non Current Assets $16M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments $14M
Short Term Investments $129M
Other Current Assets $6.2M
Other Non Current Assets -
Total Liabilities $15M
Total Current Liabilities $14M
Current Accounts Payable $6.6M
Deferred Revenue -
Current Debt -
Short Term Debt $352K
Total Non Current Liabilities $838K
Capital Lease Obligations $1.2M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.2M
Other Current Liabilities $7.4M
Other Non Current Liabilities -
Total Shareholder Equity $176M
Treasury Stock -
Retained Earnings -$369M
Common Stock -
Common Stock Shares Outstanding $52M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$51M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.1M
Capital Expenditures $655K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $53M
Cashflow From Financing $313K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$59M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue $1.1M
Costof Goods And Services Sold $1.1M
Operating Income -$85M
Selling General And Administrative $27M
Research And Development $59M
Operating Expenses $85M
Investment Income Net -
Net Interest Income $11M
Interest Income $11M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.1M
Income Before Tax -$75M
Income Tax Expense -$16M
Interest And Debt Expense -
Net Income From Continuing Operations -$59M
Comprehensive Income Net Of Tax -
Ebit -$85M
Ebitda -$84M
Net Income -$59M

PMVP News

PMVP Profile

Pmv Pharmaceuticals Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

PMV Pharmaceuticals, Inc. is a cutting-edge precision oncology company based in Cranbury, New Jersey, that specializes in the development of targeted small molecule therapies targeting p53 mutations prevalent in various forms of cancer. Leveraging advanced technological platforms and comprehensive tumor biology insights, PMV aims to redefine cancer treatment through innovative, tumor-agnostic therapies, addressing substantial unmet medical needs in oncology. The company's strategic commitment to pioneering therapeutic solutions positions it to significantly influence cancer care and improve outcomes for patients harboring these critical mutations.

WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
PLUG
-7.12%
$2.08
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
AAL
-3.29%
$12.34
RGTI
-3.10%
$24.69
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
BTBT
-4.56%
$2.30
HBAN
-2.73%
$15.30
HIMS
-3.78%
$35.58
MU
-1.97%
$241.95
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
SMR
-6.19%
$21.06
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
NBIS
+2.92%
$85.98
JOBY
-3.60%
$13.89
WTO
+25.52%
$0.03
LPTX
+368.57%
$2.05
APLT
+30.18%
$0.28
AMIX
+58.18%
$1.15
KXIN
-7.64%
$0.28
NVDA
-1.87%
$186.60
ONDS
-12.88%
$6.25
CHR
-2.66%
$0.04
ASST
-3.70%
$1.04
TSLA
+1.13%
$408.92
GLMD
+0.96%
$1.05
PFE
+0.07%
$25.08
SOFI
-2.80%
$27.04
DVLT
+1.91%
$1.86
F
-2.35%
$12.88
PLUG
-7.12%
$2.08
INTC
-2.28%
$34.71
GNS
-9.87%
$0.77
QUBT
+8.49%
$11.50
ACHR
-5.83%
$7.42
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
DNN
-3.62%
$2.39
BYND
-3.70%
$1.04
BITF
+3.48%
$2.67
AMZN
-0.77%
$232.87
BMNR
-10.02%
$30.95
RIVN
-1.58%
$14.87
ETHD
+8.79%
$5.69
DFLI
-1.27%
$0.80
ASBP
-14.11%
$0.09
KVUE
-2.52%
$16.24
MARA
-4.00%
$11.51
NIO
-1.29%
$6.08
GOOGL
+3.11%
$285.02
ADAP
-15.14%
$0.05
SNAP
-4.55%
$8.18
HPE
-7.00%
$21.23
PLTR
-1.58%
$171.25
BURU
-13.34%
$0.21
RIG
+1.74%
$4.08
TLRY
-4.62%
$1.03
AAPL
-1.81%
$267.46
GPUS
-14.84%
$0.23
CIFR
-0.06%
$14.35
AAL
-3.29%
$12.34
RGTI
-3.10%
$24.69
GRAB
-1.47%
$5.33
WULF
+0.54%
$11.05
HOOD
-5.33%
$115.97
RMBL
+60.50%
$3.21
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
AMD
-2.54%
$240.52
MSPR
+18.40%
$0.53
PLTD
+1.75%
$6.96
WBD
-1.25%
$22.74
BAC
-2.14%
$51.48
BTG
-2.68%
$3.99
CAN
-4.37%
$0.85
XPEV
-10.31%
$22.43
SRM
+53.27%
$10.30
T
-0.46%
$25.47
GOOG
+3.11%
$285.60
IREN
+2.24%
$47.41
NOK
-1.04%
$6.66
SMCI
-6.37%
$34.10
BBD
-1.63%
$3.62
AMC
-4.82%
$2.17
BTBT
-4.56%
$2.30
HBAN
-2.73%
$15.30
HIMS
-3.78%
$35.58
MU
-1.97%
$241.95
QBTS
-3.30%
$22.83
BTE
-4.43%
$3.02
OWL
-5.81%
$13.77
SOUN
-6.08%
$11.43
CRWV
-2.62%
$75.33
CSCO
-0.28%
$77.78
WLGS
-5.57%
$0.04
IONZ
-3.07%
$5.04
CLSK
-3.19%
$10.61
VALE
-1.05%
$12.17
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
NFLX
-0.83%
$110.29
EOSE
-5.79%
$13.00
ABEV
-0.39%
$2.54
APLD
-3.02%
$22.93
RXRX
-0.48%
$4.12
CLF
+2.23%
$10.97
SMR
-6.19%
$21.06
IVVD
+20.85%
$2.84
CRCL
-6.47%
$76.59
AFMD
-34.94%
$0.18
AMCR
-0.35%
$8.45
QS
-3.57%
$12.95
KDP
-0.62%
$26.96
NBIS
+2.92%
$85.98
JOBY
-3.60%
$13.89

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.